NDT Advance Access originally published online on July 4, 2006
Nephrology Dialysis Transplantation 2006 21(10):2795-2799; doi:10.1093/ndt/gfl325
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Effect of tranilast in early-stage diabetic nephropathy
Department of Nephrology, Iwate Prefectural Central Hospital, 1-4-1, Ueda, Morioka 020-0066, Japan
Correspondence and offprint requests to: Jun Soma, MD, PhD, Department of Nephrology, Iwate Prefectural Central Hospital, 1-4-1, Ueda, Morioka 020-0066, Japan. Email: sjun{at}chuo-hp.pref.iwate.jp
Background. Tranilast is an antifibrotic drug known to suppress collagen synthesis by fibroblasts by interfering with the effects of TGF-ß. We recently reported that it slowed the progression rate of advanced diabetic nephropathy (DN) by reducing the accumulation of collagens in renal tissue. The present study was undertaken to examine the effect of tranilast on early-stage DN.
Methods. Among out-patients with diabetes mellitus, we selected patients with (i) urinary albumin excretion of 30–1000 mg/g creatinine (/gCr) in the first morning urine, (ii) serum creatinine (SCr) 
1.2 mg/dl and no haematuria and (iii) currently taking an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. Twenty patients fulfilled the criteria, of whom 10 were selected at random and commenced on tranilast [100 mg, 3 times daily; T(+) group]. The remaining 10 patients comprised the T(–) group. Excretion of both urinary type IV collagen (U-IV) and albumin (U-A) in the first morning urine was measured every 3 months. The follow-up period was 1 year.
Results. At baseline, no significant differences were observed in SCr, HbA1c, blood pressure and U-A excretion between the T(+) and T(–) groups, but U-IV excretion in the T(+) group was higher than in the T(–) group (6.4 ± 0.66 vs 3.7 ± 0.36 µg/gCr, mean ± SEM, P < 0.01). At 1 year, SCr was not different from the baseline in either group. In the T(+) group, however, excretion rates of both U-IV and U-A tended to decrease with time, and after 1 year, were significantly decreased compared with excretion at baseline (U-A: 279 ± 78 to 191 ± 62 mg/gCr; P = 0.049, U-IV: 6.4 ± 0.66 to 4.4 ± 0.99 µg/gCr; P = 0.02). In contrast, in the T(–) group, excretion of both U-A and U-IV tended to increase with time. The changes of both U-A and U-IV excretions in the two groups took statistically different trends through tranilast treatment (P = 0.01 and P = 0.04, respectively).
Conclusions. Our results suggest that tranilast could be therapeutically beneficial in early-stage DN.
Keywords: albuminuria; collagen; diabetic nephropathy; extracellular matrix; tranilast
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Boor, K. Sebekova, T. Ostendorf, and J. Floege Treatment targets in renal fibrosis Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3391 - 3407. [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kelly, Y. Zhang, K. Connelly, A. J. Cox, J. Martin, H. Krum, and R. E. Gilbert Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2860 - H2869. [Abstract] [Full Text] [PDF]
|
|